Foundational Pharmacy Strategies’ Christine Johnston on how rebate structures, pending legislation, and a stalled pipeline are reshaping — and threatening — the biosimilar market heading into 2027.
News|Articles|July 1, 2006
Formulary June 2008 BPA Statement
Formulary June 2008 BPA Statement
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Why biosimilars keep losing ground to brand-name rivals: A Q&A with Christine Johnston, MBA
2
Melanoma care is shifting to risk-based screening and treatment before surgery | Fall Clinical Derm 2026
3
Choosing a first biologic for HS, as recommended by Jennifer Hsiao, M.D. | Fall Clinical Derm 2026
4
Experts urge earlier JAK inhibitor use in AD and vitiligo | Fall Clinical Derm 2026
5